SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer
Clinical trial NCT07535632 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07535632
- Sponsor
- Shanghai Zhongshan Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-01
- Primary completion
- 2028-06-01
- Enrollment
- 58
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.